UM

Browse/Search Results:  1-9 of 9 Help

Selected(0)Clear Items/Page:    Sort:
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms Journal article
Pharmacology and Therapeutics, 2021,Volume: 219
Authors:  Huang,Mu Yang;  Jiang,Xiao Ming;  Wang,Bing Lin;  Sun,Yang;  Lu,Jin Jian
Favorite |  | TC[WOS]:1 TC[Scopus]:1 | Submit date:2021/03/02
challenge  combination therapy  immunotherapy  mechanism  NSCLC  PD-1/PD-L1  
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms Journal article
Pharmacology and Therapeutics, 2021,Volume: 219
Authors:  Huang,Mu Yang;  Jiang,Xiao Ming;  Wang,Bing Lin;  Sun,Yang;  Lu,Jin Jian
Favorite |  | TC[WOS]:1 TC[Scopus]:1 | Submit date:2021/03/02
challenge  combination therapy  immunotherapy  mechanism  NSCLC  PD-1/PD-L1  
Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells Journal article
Phytomedicine, 2021,Volume: 80
Authors:  Yuan,Luo Wei;  Jiang,Xiao Ming;  Xu,Yu Lian;  Huang,Mu Yang;  Chen,Yu Chi;  Yu,Wei Bang;  Su,Min Xia;  Ye,Zi Han;  Chen,Xiuping;  Wang,Yitao;  Lu,Jin Jian
Favorite |  | TC[WOS]:0 TC[Scopus]:0 | Submit date:2021/03/01
IFN-γ  Licochalcone A  Natural products  PD-L1  Protein synthesis inhibitor  ROS  
Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells Journal article
Chinese Journal of Natural Medicines, 2020,Volume: 18,Issue: 7,Page: 517-525
Authors:  CHEN,Yu Chi;  HUANG,Mu Yang;  ZHANG,Le Le;  FENG,Zhe Ling;  JIANG,Xiao Ming;  YUAN,Luo Wei;  HUANG,Run Yue;  LIU,Bo;  YU,Hua;  WANG,Yi Tao;  CHEN,Xiu Ping;  LIN,Li Gen;  LU,Jin Jian
Favorite |  | TC[WOS]:2 TC[Scopus]:2 | Submit date:2021/03/01
c-Jun  JNK  Lung cancer  Nagilactone E  Programmed death ligand 1  
Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity Journal article
Acta Pharmacologica Sinica, 2020,Volume: 41,Issue: 5,Page: 698-705
Authors:  Zhang,Le le;  Guo,Jing;  Jiang,Xiao ming;  Chen,Xiu ping;  Wang,Yi tao;  Li,Ao;  Lin,Li gen;  Li,Hua;  Lu,Jin jian
Favorite |  | TC[WOS]:6 TC[Scopus]:6 | Submit date:2021/03/01
Click-iT  CMap  diterpenoids  human lung cancer A549 cell line xenograft  molecular docking  nagilactone E  protein synthesis inhibitor  RIOK2  RNA-seq  
Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus Journal article
Biochemical Pharmacology, 2020,Volume: 175
Authors:  Li,Ting;  Xu,Xiao Huang;  Guo,Xia;  Yuan,Tao;  Tang,Zheng Hai;  Jiang,Xiao Ming;  Xu,Yu Lian;  Zhang,Le Le;  Chen,Xiuping;  Zhu,Hong;  Shi,Jia Jie;  Lu,Jin Jian
Favorite |  | TC[WOS]:2 TC[Scopus]:3 | Submit date:2021/03/01
Apoptosis  c-MYC  CHOP  Lung cancer  Notch 3  
Phanginin R induces cytoprotective autophagy via JNK/C-JUN signaling pathway in non-small cell lung cancer A549 cells Journal article
Anti-Cancer Agents in Medicinal Chemistry, 2020,Volume: 20,Issue: 8,Page: 982-988
Authors:  Zhang,Le Le;  Bao,Han;  Xu,Yu Lian;  Jiang,Xiao Ming;  Li,Wei;  Zou,Liang;  Lin,Li Gen;  Lu,Jin Jian
Favorite |  | TC[WOS]:1 TC[Scopus]:2 | Submit date:2021/03/01
Anti-cancer  Autophagy  C-Jun  JNK  Non-small cell lung cancer  Phanginin R  
TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance Journal article
Acta Pharmacologica Sinica, 2020
Authors:  Jiang,Xiao ming;  Xu,Yu lian;  Yuan,Luo wei;  Zhang,Le le;  Huang,Mu yang;  Ye,Zi han;  Su,Min xia;  Chen,Xiu ping;  Zhu,Hong;  Ye,Richard D.;  Lu,Jin jian
Favorite |  | TC[WOS]:3 TC[Scopus]:2 | Submit date:2021/03/01
EGFR mutant non-small cell lung cancer  epithelial-mesenchymal transition  NF-κB  osimertinib resistance  TGFβ2  
Establishment and characterization of pemetrexed-resistant NCI-H460/PMT cells Journal article
Anti-Cancer Agents in Medicinal Chemistry, 2019,Volume: 19,Issue: 6,Page: 731-739
Authors:  Xu,Yu Lian;  Jiang,Xiao Ming;  Zhang,Le Le;  Chen,Xiuping;  Huang,Zhang Jian;  Lu,Jin Jian
Favorite |  | TC[WOS]:2 TC[Scopus]:2 | Submit date:2021/03/01
ABCB1  Chemotherapy  NSCLC  Pemetrexed  Resistance  TYMS